PHARMACYTE BIOT Reported Earnings

PHARMACYTE BIOT (PMCB) reported a loss of $0.54 per share on revenue of $0.00 million for the . .

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company. It is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). The Company's patented technology is used in the treatment of several types of cancer, including advanced, inoperable pancreatic cancer and diabetes. PharmaCyte Biotech, Inc., formerly known as Nuvilex, Inc., is based in United States.